This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Association Française des Psoriasiques | |
|---|---|
| Name | Association Française des Psoriasiques |
| Native name | Association Française des Psoriasiques |
| Type | Non-profit organization |
| Founded | 1960s |
| Headquarters | Paris, France |
| Area served | France |
| Focus | Psoriasis, patient support, advocacy |
Association Française des Psoriasiques is a French patient association dedicated to supporting people affected by psoriasis and psoriatic arthritis. The association operates in France with ties to European and international patient networks and interacts with health institutions, research bodies, pharmaceutical companies, and media outlets. It provides services to patients, advises policymakers, and collaborates with clinical researchers and professional societies.
The association traces roots to patient mobilization movements and postwar health advocacy seen alongside organizations such as Ligue nationale contre le cancer, Médecins Sans Frontières, France Assos Santé, Fondation pour la Recherche Médicale, and Red Cross (France). Early activities paralleled initiatives by Haute Autorité de Santé, Ministry of Health (France), Assurance Maladie, and regional actors like Île-de-France Regional Health Agency to integrate dermatological conditions into public health planning. Over decades the group engaged with specialist societies including French Society of Dermatology, European Academy of Dermatology and Venereology, International Federation of Psoriasis Associations, and institutions such as INSERM, CNRS, Université Paris Cité, and AP-HP.
The association’s mission echoes patient advocacy exemplified by European Patients' Forum, World Health Organization, Council of Europe, World Medical Association, and patient-rights frameworks like Charter of Patients' Rights. Objectives include improving access to dermatological care within systems like French Social Security, promoting clinical research standards influenced by European Medicines Agency, and fostering physician–patient partnerships modeled after collaborations with Société Française de Rhumatologie and Collège Français de Pédiatrie. It aims to reduce stigma through public campaigns similar to initiatives by UNESCO and European Commission awareness programs.
Services mirror those of peer organizations such as Cancer Research UK and British Skin Foundation, offering peer support, informational resources, and helplines linked to networks like European Federation of Psoriasis Associations and Alliance for Patient Access. Activities include organizing seminars with experts from Université Claude Bernard Lyon 1, conferences in partnership with European League Against Rheumatism, patient education modules referencing guidelines from National Institute for Health and Care Excellence and Haute Autorité de Santé, and public outreach comparable to campaigns by Institut Pasteur and Santé publique France. The association facilitates patient navigation in hospitals such as Hôpital Saint-Louis (Paris) and collaborates with community clinics and rehabilitation centers similar to Centre Hospitalier Universitaire de Toulouse.
Governance structures follow models used by French Red Cross and Médecins du Monde, with a board of directors, elected officers, and advisory committees including clinicians from Hôpital Cochin, researchers from Université Grenoble Alpes, and legal advisors versed in regulations like those of the Conseil d'État and European Court of Human Rights. Financial oversight interacts with funding norms seen at Caisse des Dépôts, grant processes used by Agence Nationale de la Recherche, and compliance with French association law as applied in tribunals such as Tribunal de grande instance de Paris. Volunteer coordination parallels organizing practices at Emmaüs and Restos du Cœur.
Advocacy work engages policy arenas including the Assemblée nationale, the Sénat (France), and regulatory bodies such as Haute Autorité de Santé and European Medicines Agency. The association participates in consultations alongside stakeholders like French National Institute for Health and Medical Research (INSERM), patient coalitions represented by Alliance Maladies Rares, and professional lobby groups such as Les Entreprises du Médicament (Leem). Campaigns target reimbursement decisions by Assurance Maladie, formulary inclusion decisions akin to those addressed by HAS, and public procurement processes used by Ministry of Solidarity and Health (France).
Research collaborations include partnerships with academic centers such as Université de Strasbourg, translational labs at Institut Curie, and clinical trial units associated with European Clinical Research Infrastructure Network. The association engages with pharmaceutical and biotech firms comparable to Sanofi, Novartis, AbbVie, Pfizer, and Johnson & Johnson for research funding and patient-centered trial design, while also working with regulatory science bodies like European Medicines Agency and funders such as European Commission Horizon 2020 programs. It liaises with international registries and projects similar to PsoProtect and networks like EULAR for data sharing and outcomes research.
Membership mirrors federated structures used by groups such as Croix-Rouge française and France Alzheimer, with local chapters across regions including Provence-Alpes-Côte d'Azur, Occitanie, Nouvelle-Aquitaine, Grand Est, and Bretagne. Local chapters collaborate with regional hospitals like Hôpital de la Timone, community centers, and municipal health services in cities such as Lyon, Marseille, Bordeaux, Lille, Nantes, and Strasbourg. Membership offers access to patient networks similar to European Patients' Academy (EUPATI) and volunteer training modeled on programs from France Bénévolat.
Category:Medical and health organizations based in France Category:Patient advocacy organizations